NASDAQ:PBYI - Puma Biotechnology Stock Price, Forecast & News

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology Inc (NASDAQ:PBYI) released its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.32. The biopharmaceutical company had revenue of $56.40 million for the quarter, compared to the consensus estimate of $60.21 million. Puma Biotechnology had a negative net margin of 27.76% and a negative return on equity of 275.17%. The business's revenue was down 9.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.16 EPS. View Puma Biotechnology's Earnings History.

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Puma Biotechnology.

10 equities research analysts have issued 12 month price targets for Puma Biotechnology's shares. Their forecasts range from $6.00 to $17.00. On average, they expect Puma Biotechnology's share price to reach $12.38 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Price Targets for Puma Biotechnology.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Puma Biotechnology.

Headlines about PBYI stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Puma Biotechnology earned a news impact score of -4.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Puma Biotechnology.

Puma Biotechnology saw a increase in short interest in January. As of January 31st, there was short interest totalling 7,820,000 shares, an increase of 12.4% from the January 15th total of 6,960,000 shares. Based on an average daily volume of 1,760,000 shares, the days-to-cover ratio is currently 4.4 days. Approximately 23.2% of the shares of the stock are sold short. View Puma Biotechnology's Current Options Chain.

Some companies that are related to Puma Biotechnology include Arvinas (ARVN), IGM Biosciences (IGMS), Heron Therapeutics (HRTX), Zymeworks (ZYME), Alder Biopharmaceuticals (ALDR), Tricida (TCDA), Esperion Therapeutics (ESPR), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT), Constellation Pharmaceuticals (CNST), Dicerna Pharmaceuticals (DRNA), Innoviva (INVA), Theravance Biopharma (TBPH), Madrigal Pharmaceuticals (MDGL) and ZEALAND PHARMA/S (ZEAL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (Incy), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG).

Puma Biotechnology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (9.00%), Fred Alger Management LLC (4.55%), Palo Alto Investors LP (3.46%), Acadian Asset Management LLC (2.15%), Goldman Sachs Group Inc. (1.97%) and Geode Capital Management LLC (1.45%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler, Douglas M Hunt and Richard Paul Bryce. View Institutional Ownership Trends for Puma Biotechnology.

PBYI stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., UBS Group AG, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Point72 Asset Management L.P., FMR LLC, Rafferty Asset Management LLC and Palo Alto Investors LP. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.

PBYI stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Acadian Asset Management LLC, Geode Capital Management LLC, Credit Suisse AG, Fred Alger Management LLC, Oxford Asset Management LLP, Renaissance Technologies LLC and Schonfeld Strategic Advisors LLC. View Insider Buying and Selling for Puma Biotechnology.

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PBYI stock can currently be purchased for approximately $10.76.

Puma Biotechnology has a market capitalization of $419.22 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.View Additional Information About Puma Biotechnology.

The official website for Puma Biotechnology is http://www.pumabiotechnology.com/.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]